Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Quest Diagnostics (NY: DGX )

126.41 -0.57 (-0.45%)
Streaming Delayed Price Updated: 11:19 AM EDT, Apr 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Quest Diagnostics

< Previous 1 2 3 4 5 6 7 8 9 Next >
Benzinga's Top Ratings Upgrades, Downgrades For January 23, 2023
Via Benzinga
Down 40% in 2022, Can Exact Sciences Recover in 2023?
Investors are attracted to its leading position in the market for early cancer detection, but the persistent losses its been reporting are enough to make anyone nervous. 
Via The Motley Fool
Analyst Ratings for Quest Diagnostics
Via Benzinga
Where Quest Diagnostics Stands With Analysts
Via Benzinga
Golden Cross Appears Before Quest Diagnostics Investors
Via Benzinga
Where Quest Diagnostics Stands With Analysts
Via Benzinga
Why Quest Diagnostics Stock Jumped Today
Growth in the lab testing titan's core business is accelerating. 
Via The Motley Fool
These 2 Defensive Plays Are Highlights Of CNBC's 'Final Trades'
On CNBC’s "Halftime Report: Final Trades," Shannon Saccocia of Boston Private said Quest Diagnostics Inc (NYSE: DGX) is expected to grow 4% to 5% 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 17, 2022
Upgrades 
Via Benzinga
Quest Diagnostics Q3 Earnings Surpass Expectations, Raises Annual Guidance
Via Benzinga
Quest Diagnostics To Plunge 16%? Here Are 5 Other Price Target Changes For Thursday
Via Benzinga
DermTech and Sonora Quest Laboratories Expand Access to Innovative Melanoma Detection Test
From DermTech, Inc.
Via Business Wire
Here’s Why Quest Diagnostics Stock Should Be in Your Portfolio
Medical diagnostic lab company Quest Diagnostic (NYSE: DGX) stock has been trading within a boxed range from $126 to $146 for the majority of 2022. 
Via MarketBeat
Exposures COVID-19
Quest Diagnostics Lifts Annual Guidance On Higher COVID-19 Test Revenue Anticipation
Via Benzinga
Quest Diagnostics: Q3 Earnings Insights
Quest Diagnostics (NYSE:DGX) reported its Q3 earnings results on Thursday, October 20, 2022 at 06:45 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Earnings Scheduled For October 20, 2022
Companies Reporting Before The Bell • ABB (NYSE:ABB) is estimated to report quarterly earnings at $0.38 per share on revenue of $7.35 billion. 
Via Benzinga
A Preview Of Quest Diagnostics's Earnings
Quest Diagnostics (NYSE:DGX) is set to give its latest quarterly earnings report on Thursday, 2022-10-20. Here's what investors need to know before the announcement. Analysts estimate that Quest... 
Via Benzinga
Eli Lilly, EQT, Cash Cows ETF, Northrop Grumman And This Diagnostics Company Feature On CNBC's Final Trade
On CNBC’s “Halftime Report Final Trades,” Bryn Talkington of Requisite Capital Management said Pacer US Cash Cows 100 ETF (BATS: COWZ) is “a factor-b 
Via Benzinga
What Fast Food And Entertainment Giants Did Traders Pick For CNBC's Fast Money Call Of The Day
CNBC’s "Fast Money Halftime Report" delivers market-moving news to investors. The commentary delivered by hosts of the show often moves the stocks mentioned. The information is collected and refined... 
Via Benzinga
FDA To Review Smaller Number Of Emergency Use Requests For COVID-19 Tests
Via Benzinga
COVID-19 Complacency Pushes Identification Of New Variants To Back Seat, WHO Warns
The World Health Organization (WHO) warned that it struggles to identify and 
Via Benzinga
Achievers and Quest Diagnostics Win Gold in the 2022 Brandon Hall Group Excellence Technology Awards
From Achievers
Via Business Wire
Quest Becomes Exclusive Validator For Results From The Hound Cannabis Breathalyzer
Hound Labs, creator of the Hound Cannabis Breathalyzer, entered into an agreement with Quest Diagnostics (NYSE: DGX), a provider of diagnostic information services. 
Via Benzinga
No More Free COVID-19 At-Home Tests, Federal Government Says
CNBC reported that the federal government is set to suspend its offer of free at-home COVID-19 tests by Friday, September 2, without congressional au 
Via Benzinga
3 Top Monkeypox Stocks to Buy Right Now
With cases of a frightening disease spreading to all 50 states, it’s now time to consider the top monkeypox stocks to buy right now. 
Via InvestorPlace
3 Monkeypox Stocks to Buy as Biden Declares Public Health Emergency
Monkeypox stocks are about to rise now that the White House has declared the virus a public health emergency. Here are the stocks to watch. 
Via InvestorPlace
Drug Testing At Work Is A Thing Of The Past, Study Finds
According to a study conducted by Quest Diagnostics Inc (NYSE: DGX), drug use among American employees, as measured by the percentage of employees who tested positive in urine drug tests, hit a 
Via Benzinga
4 Analysts Have This to Say About Quest Diagnostics
Analysts have provided the following ratings for Quest Diagnostics (NYSE:DGX) within the last quarter: 
Via Benzinga
Quest Diagnostics: Q2 Earnings Insights
  Quest Diagnostics (NYSE:DGX) reported its Q2 earnings results on Thursday, July 21, 2022 at 06:45 AM. Here's what investors need to know about the announcement. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.